A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP

Summary

The main purpose of this study is to compare empasiprubart and IVIg for treating people with CIDP. This study consists of a Part A where participants will either receive empasiprubart and a placebo resembling IVIg, or IVIg and a placebo resembling empasiprubart for 24 weeks (6 months). Following Part A, participants will enter Part B in which all participants will receive empasiprubart for 96 weeks (24 months). More information can be found here: https://clinicaltrials.argenx.com/emvigorate

Timeline

Start

2025-08-22

Primary completion

2027-09

Completion

2030-09

Drugs

Indications